This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.Need a new registration confirmation email? Click here

Novo Nordisk A/S Reaches New 52-Week High (NVO)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK (
TheStreet) --
Novo Nordisk A/S (NYSE:
NVO) hit a new 52-week high Tuesday as it is currently trading at $167.13, above its previous 52-week high of $166.03 with 14,052 shares traded as of 9:35 a.m. ET. Average volume has been 288,900 shares over the past 30 days.

Novo Nordisk A/S has a market cap of $93.26 billion and is part of the
health care sector and
drugs industry. Shares are up 43% year to date as of the close of trading on Monday.

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products in Denmark and internationally. The company operates in two segments, Diabetes Care and Biopharmaceuticals. The company has a P/E ratio of four, below the average drugs industry P/E ratio of 27.7 and below the S&P 500 P/E ratio of 17.7.

ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

TheStreet Ratings rates Novo Nordisk A/S as a
buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, increase in net income, notable return on equity, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. You can view the full
Novo Nordisk A/S Ratings Report.